In some cases, sarcomas are difficult to diagnose by pathological examination alone, and the identification of an NTRK fusion gene by CGP testing has led to a more accurate diagnosis and the potential for TRK inhibitor therapy. The gene discussed is TPM3; the disease is sarcoma.